◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Cytokinetics Inc (CYTK) EBITDA 2006–TTM

Name: Cytokinetics Inc (CYTK) ebitda history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Cytokinetics Inc annual ebitda for fiscal 2025 was -$775 million, a decrease of 57.2% from -$493 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

CYTK Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
EBITDA	—	($775M)	($493M)	($457M)	($329M)	($176M)	($87M)	($93M)	($83M)	($109M)	$19M	($37M)	($14M)	($33M)	($40M)	($47M)	($48M)	$27M	($53M)	($45M)	($54M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($169M)	($180M)	($277M)	($108M)	($136M)	($125M)	($136M)	($117M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

AXSM EBITDA — Axsome Therapeutics Inc
APGE EBITDA — Apogee Therapeutics, Inc. Common Stock
KRYS EBITDA — Krystal Biotech Inc
KYMR EBITDA — Kymera Therapeutics Inc
ARWR EBITDA — Arrowhead Pharmaceuticals Inc
PTGX EBITDA — Protagonist Therapeutics Inc

More CYTK metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All CYTK financial statements → Interactive CYTK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.